# Ozone Therapy in Refractory Ischemic Heart Disease.

> **NCT03660657** · PHASE2,PHASE3 · TERMINATED · sponsor: **Bernardino Clavo, MD, PhD** · enrollment: 1 (actual)

## Conditions studied

- Ischemic Heart Disease

## Interventions

- **DRUG:** Ozone
- **DRUG:** Oxygen

## Key facts

- **NCT ID:** NCT03660657
- **Lead sponsor:** Bernardino Clavo, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-26
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Very low recruitment. During COVID-19 pandemic these are patients of high risk.
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660657, "Ozone Therapy in Refractory Ischemic Heart Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03660657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*